Rakotoarisoa L, Weiss L, Lefebvre F, Porzio M, Renaud-Picard B, Ravoninjatovo B, Abely M, Danner-Boucher I, Dubois S, Troussier F, Prevotat A, Rault G, Kessler R, Kessler L

J Diabetes Complications. 2024 02 14;38(4):108703

Screening strategies for glucose tolerance abnormalities and diabetes in people with cystic fibrosis.

Weiss L, Reix P, Mosnier-Pudar H, Ronsin O, Beltrand J, Reynaud Q, Mely L, Burgel PR, Stremler N, Rakotoarisoa L, Galderisi A, Perge K, Bendelac N, Abely M, Kessler L

Diabetes Metab. 2023 04 6;:101444

Nutritional status at age 1 year in patients born with esophageal atresia: A population-based, prospective cohort study.

Depoortere S, Lapillonne A, Sfeir R, Bonnard A, Gelas T, Panait N, Rabattu PY, Guignot A, Lamireau T, Irtan S, Habonimana E, Breton A, Fouquet V, Allal H, Elbaz F, Talon I, Ranke A, Abely M, Michel JL, Lirussi Borgnon J, Buisson P, Schmitt F, Lardy H, Petit T, Chaussy Y, Borderon C, Levard G, Cremillieux C, Tolg C, Breaud J, Jaby O, Grossos C, De Vries P, Arnould M, Pelatan C, Geiss S, Laplace C, Kyheng M, Nicolas A, Aumar M, Gottrand F

Front Pediatr. 2022 08 4;10:969617

Clinical practice versus guidelines for the screening of cystic fibrosis-related diabetes: A French survey from the 47 centers.

Weiss L, Ronsin O, Reynaud Q, Abely M, Mely L, Burgel PR, Beltrand J, Kessler L

J Clin Transl Endocrinol. 2022 Jun;28:100298

Comparison of continuous glucose monitoring in cystic fibrosis patients with or without pancreatic exocrine insufficiency.

Rakotoarisoa L, Weiss L, Lefebvre F, Porzio M, Ravoninjatovo B, Abely M, Danner Boucher I, Dubois S, Troussier F, Gilles R, Prevotat A, Kessler L

Horm Metab Res. 2022 Mar 10;:

Chest physiotherapy enhances detection of in nonexpectorating children with cystic fibrosis.

Marguet C, Houdouin V, Pin I, Reix P, Huet F, Mittaine M, Ramel S, Wizla-Derambure N, Abely M, Dalphin ML, Fayon M, Bihouée T, Le Bourgeois M, Deneuville E, Corvol H, Laurans M, Couderc L, Leroux E, Lémée L

ERJ Open Res. 2021 Jan;7(1):

Clinical response to lumacaftor-ivacaftor in patients with cystic fibrosis according to baseline lung function.

Burgel PR, Durieu I, Chiron R, Mely L, Prevotat A, Murris-Espin M, Porzio M, Abely M, Reix P, Marguet C, Macey J, Sermet-Gaudelus I, Corvol H, Bui S, Biouhee T, Hubert D, Munck A, Lemonnier L, Dehillotte C, Silva JD, Paillasseur JL, Martin C,

J. Cyst. Fibros.. 2020 Jun 23;:

Effect of one-year lumacaftor-ivacaftor treatment on glucose tolerance abnormalities in cystic fibrosis patients.

Misgault B, Chatron E, Reynaud Q, Touzet S, Abely M, Melly L, Dominique S, Troussier F, Ronsin-Pradel O, Gerardin M, Mankikian J, Cosson L, Chiron R, Bounyar L, Porzio M, Durieu I, Weiss L, Kessler R, Kessler L

J. Cyst. Fibros.. 2020 Mar 19;:

Real-Life Safety and Effectiveness of Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis.

Burgel PR, Munck A, Durieu I, Chiron R, Mely L, Prevotat A, Murris-Espin M, Porzio M, Abely M, Reix P, Marguet C, Macey J, Sermet-Gaudelus I, Corvol H, Bui S, Lemonnier L, Dehilotte C, Da Silva J, Paillasseur JL, Hubert D,

Am. J. Respir. Crit. Care Med.. 2019 Oct 11;:

[An indolent and fluctuating subcutaneous mass of the skull in a 5-year-old patient: Diagnostic approach and difficulties].

Beck J, Pluchart C, Durlach A, Durez O, Abely M, Pietrement C

Arch Pediatr. 2017 Apr;24(4):367-370

Inhibition of the NOTCH pathway using γ-secretase inhibitor RO4929097 has limited antitumor activity in established glial tumors.

Dantas-Barbosa C, Bergthold G, Daudigeos-Dubus E, Blockus H, Boylan JF, Ferreira C, Puget S, Abely M, Vassal G, Grill J, Geoerger B

Anticancer Drugs. 2015 Mar;26(3):272-83

[Mild cystic fibrosis: genetics - extending follow-up is necessary].

Gaillard D, Clavel C, Bessaci-Kabouya K, Abély M

Arch Pediatr. 2009 Apr;16(4):387-90

Pr ABELY Michel

Fiche personne

coordonnées

Territoire

Statut

affiliation

équipes/plateformes

Recherche

Publications

Early glucose abnormalities revealed by continuous glucose monitoring associate with lung function decline in cystic fibrosis: A five-year prospective study.

Screening strategies for glucose tolerance abnormalities and diabetes in people with cystic fibrosis.

Nutritional status at age 1 year in patients born with esophageal atresia: A population-based, prospective cohort study.

Clinical practice versus guidelines for the screening of cystic fibrosis-related diabetes: A French survey from the 47 centers.

Comparison of continuous glucose monitoring in cystic fibrosis patients with or without pancreatic exocrine insufficiency.

Chest physiotherapy enhances detection of in nonexpectorating children with cystic fibrosis.

Clinical response to lumacaftor-ivacaftor in patients with cystic fibrosis according to baseline lung function.

Effect of one-year lumacaftor-ivacaftor treatment on glucose tolerance abnormalities in cystic fibrosis patients.

Real-Life Safety and Effectiveness of Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis.

[An indolent and fluctuating subcutaneous mass of the skull in a 5-year-old patient: Diagnostic approach and difficulties].

[Pancreatic infringement exocrine and endocrine in cystic fibrosis].

Causes of death in French cystic fibrosis patients: The need for improvement in transplantation referral strategies!

Rhinovirus-associated pulmonary exacerbations show a lack of FEV1 improvement in children with cystic fibrosis.

Management of pancreatic, gastrointestinal and liver complications in adult cystic fibrosis.

[National consensus regarding azithromycin use in cystic fibrosis].

Inhibition of the NOTCH pathway using γ-secretase inhibitor RO4929097 has limited antitumor activity in established glial tumors.

[Mild cystic fibrosis: genetics - extending follow-up is necessary].